Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2021-03-18 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, RedHill Biopharma Ltd. It includes a press release titled 'RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights.' Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F. The document length is 2218 characters, which is relatively short and primarily contains a press release summary rather than detailed financial statements or comprehensive analysis. The content is an announcement of financial results rather than the full report itself. According to the classification rules, such documents are best classified as Regulatory Filings (RNS) because they do not contain the full annual or quarterly report but rather an announcement or press release of financial results.
2021-03-18 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about hosting a webcast for fourth quarter and full-year 2020 financial results and operational highlights. The document is short (2207 characters) and primarily serves as an announcement of an event (webcast) rather than containing actual financial statements or detailed financial data. It does not contain the full financial report or detailed analysis. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into other specific categories like Earnings Release or Interim Report. It is not a report publication announcement since it does not mention the report is attached or available elsewhere, but rather announces a webcast event.
2021-03-11 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about upcoming conference presentations. The document length is only 2163 characters, which is quite short and does not contain any detailed financial data or substantive report content. It primarily serves as an announcement of a press release and conference participation, not a full report or detailed financial disclosure. According to the rules, short documents that announce or attach other materials without containing the full report should be classified as Regulatory Filings (RNS). Therefore, this document fits best under Regulatory Filings (RNS).
2021-03-05 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes exhibits related to an amended underwriting agreement and legal opinions, which are typical for disclosures related to financing or capital raising activities. The document length is 2740 characters, which is relatively short and mainly serves as a report of these exhibits rather than a full financial report. There is no detailed financial data or comprehensive report content. The presence of an underwriting agreement strongly indicates a capital or financing update. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2021-03-04 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) related to a public offering of American Depositary Shares (ADSs) by RedHill Biopharma Ltd. It details the terms of the offering, underwriting arrangements, risk factors, use of proceeds, and other related information. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering. It is not an annual or quarterly report, earnings release, or management discussion. It is not a regulatory filing unrelated to capital raising, nor is it a proxy, voting result, or governance document. The document is a detailed offering prospectus supplement, which fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and financing activities. The document length (15,000 characters) and content confirm it is the actual offering document, not just an announcement or notice. Therefore, the correct classification is CAP with high confidence.
2021-03-03 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Free Writing Prospectus (FWP) dated March 2, 2021, related to a preliminary prospectus supplement and a registration statement. It announces an increase in a previously announced public offering of American Depositary Shares by RedHill Biopharma. The content focuses on the details of the offering, underwriting, use of proceeds, and regulatory filing references (Form F-3). There are no financial statements or detailed financial performance data presented, nor is this a full annual or quarterly report. The document is a disclosure related to capital raising activities and financing updates. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 9646 characters, which is substantive and not merely a brief announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2021-03-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.